Suppr超能文献

炭疽二氢叶酸还原酶的三元MTX.NADPH复合物的X射线结构:用于双位点抑制剂设计的药效团。

X-ray structure of the ternary MTX.NADPH complex of the anthrax dihydrofolate reductase: a pharmacophore for dual-site inhibitor design.

作者信息

Bennett Brad C, Wan Qun, Ahmad Md Faiz, Langan Paul, Dealwis Chris G

机构信息

Department of Pharmacology, School of Medicine, Case Western Reserve University, 10900 Euclid Avenue, Cleveland, OH 44106-4965, USA.

出版信息

J Struct Biol. 2009 May;166(2):162-71. doi: 10.1016/j.jsb.2009.01.001.

Abstract

For reasons of bioterrorism and drug resistance, it is imperative to identify and develop new molecular points of intervention against anthrax. Dihydrofolate reductase (DHFR) is a highly conserved enzyme and an established target in a number of species for a variety of chemotherapeutic programs. Recently, the crystal structure of Bacillus anthracis DHFR (baDHFR) in complex with methotrexate (MTX) was determined and, based on the structure, proposals were made for drug design strategies directed against the substrate-binding site. However, little is gleaned about the binding site for NADPH, the cofactor responsible for hydride transfer in the catalytic mechanism. In the present study, X-ray crystallography at 100 K was used to determine the structure of baDHFR in complex with MTX and NADPH. Although the NADPH binding mode is nearly identical to that seen in other DHFR ternary complex structures, the adenine moiety adopts an off-plane tilt of nearly 90 degrees and this orientation is stabilized by hydrogen bonds to functionally conserved Arg residues. A comparison of the binding site, focusing on this region, between baDHFR and the human enzyme is discussed, with an aim at designing species-selective therapeutics. Indeed, the ternary model, refined to 2.3 A resolution, provides an accurate template for testing the feasibility of identifying dual-site inhibitors, compounds that target both the substrate and cofactor-binding site. With the ternary model in hand, using in silico methods, several compounds were identified which could potentially form key bonding contacts in the substrate and cofactor-binding sites. Ultimately, two structurally distinct compounds were verified that inhibit baDHFR at low microM concentrations. The apparent Kd for one of these, (2-(3-(2-(hydroxyimino)-2-(pyridine-4-yl)-6,7-dimethylquinoxalin-2-yl)-1-(pyridine-4-yl)ethanone oxime), was measured by fluorescence spectroscopy to be 5.3 microM.

摘要

出于生物恐怖主义和耐药性的原因,识别和开发针对炭疽的新分子干预靶点势在必行。二氢叶酸还原酶(DHFR)是一种高度保守的酶,在许多物种中是多种化疗方案的既定靶点。最近,确定了炭疽芽孢杆菌DHFR(baDHFR)与甲氨蝶呤(MTX)复合物的晶体结构,并基于该结构提出了针对底物结合位点的药物设计策略。然而,关于NADPH的结合位点了解甚少,NADPH是催化机制中负责氢化物转移的辅因子。在本研究中,利用100K下的X射线晶体学确定了baDHFR与MTX和NADPH复合物的结构。尽管NADPH的结合模式与其他DHFR三元复合物结构中所见的模式几乎相同,但腺嘌呤部分采用了近90度的面外倾斜,并且这种取向通过与功能保守的精氨酸残基的氢键得以稳定。讨论了baDHFR与人酶之间结合位点的比较,重点关注该区域,旨在设计物种选择性疗法。实际上,精修至2.3埃分辨率的三元模型为测试识别双位点抑制剂(即同时靶向底物和辅因子结合位点的化合物)的可行性提供了准确模板。有了三元模型,利用计算机模拟方法,鉴定了几种可能在底物和辅因子结合位点形成关键键合接触的化合物。最终,验证了两种结构不同的化合物在低微摩尔浓度下抑制baDHFR。其中一种化合物(2-(3-(2-(羟基肟基)-2-(吡啶-4-基)-6,7-二甲基喹喔啉-2-基)-1-(吡啶-4-基)乙酮肟)的表观解离常数通过荧光光谱法测得为5.3微摩尔。

相似文献

2
Crystal structure of the anthrax drug target, Bacillus anthracis dihydrofolate reductase.
J Med Chem. 2007 Sep 6;50(18):4374-81. doi: 10.1021/jm070319v. Epub 2007 Aug 14.
4
Structure-based enzyme inhibitor design: modeling studies and crystal structure analysis of Pneumocystis carinii dihydrofolate reductase ternary complex with PT653 and NADPH.
Acta Crystallogr D Biol Crystallogr. 2002 Jun;58(Pt 6 Pt 2):946-54. doi: 10.1107/s090744490200505x. Epub 2002 May 29.
10
Structural Characterization of Dihydrofolate Reductase Complexes by Top-Down Ultraviolet Photodissociation Mass Spectrometry.
J Am Chem Soc. 2015 Jul 22;137(28):9128-35. doi: 10.1021/jacs.5b04628. Epub 2015 Jul 9.

引用本文的文献

1
Recent Progress in Regulating the Activity of Enzymes with Photoswitchable Inhibitors.
Molecules. 2024 Sep 24;29(19):4523. doi: 10.3390/molecules29194523.
2
Solution Ionic Strength Can Modulate Functional Loop Conformations in Dihydrofolate Reductase.
J Phys Chem B. 2024 May 2;128(17):4111-4122. doi: 10.1021/acs.jpcb.4c00677. Epub 2024 Apr 23.
3
Hypothesis-Driven, Structure-Based Design in Photopharmacology: The Case of eDHFR Inhibitors.
J Med Chem. 2022 Mar 24;65(6):4798-4817. doi: 10.1021/acs.jmedchem.1c01962. Epub 2022 Mar 8.
4
New Trimethoprim-Like Molecules: Bacteriological Evaluation and Insights into Their Action.
Antibiotics (Basel). 2021 Jun 12;10(6):709. doi: 10.3390/antibiotics10060709.
5
Advances in Applying Computer-Aided Drug Design for Neurodegenerative Diseases.
Int J Mol Sci. 2021 Apr 28;22(9):4688. doi: 10.3390/ijms22094688.
7
Classification of ligand molecules in PDB with graph match-based structural superposition.
J Struct Funct Genomics. 2016 Dec;17(4):135-146. doi: 10.1007/s10969-016-9209-x. Epub 2016 Dec 23.
8
Charged Nonclassical Antifolates with Activity Against Gram-Positive and Gram-Negative Pathogens.
ACS Med Chem Lett. 2016 May 5;7(7):692-6. doi: 10.1021/acsmedchemlett.6b00120. eCollection 2016 Jul 14.
9
Utility of the Biosynthetic Folate Pathway for Targets in Antimicrobial Discovery.
Antibiotics (Basel). 2014 Jan 21;3(1):1-28. doi: 10.3390/antibiotics3010001.
10
Modified 2,4-diaminopyrimidine-based dihydrofolate reductase inhibitors as potential drug scaffolds against Bacillus anthracis.
Bioorg Med Chem. 2015 Jan 1;23(1):203-11. doi: 10.1016/j.bmc.2014.11.009. Epub 2014 Nov 11.

本文引用的文献

1
Processing of X-ray diffraction data collected in oscillation mode.
Methods Enzymol. 1997;276:307-26. doi: 10.1016/S0076-6879(97)76066-X.
2
Dual binding site inhibitors of B-RAF kinase.
Bioorg Med Chem Lett. 2008 May 1;18(9):2825-9. doi: 10.1016/j.bmcl.2008.04.002. Epub 2008 Apr 4.
3
In vitro efficacy of new antifolates against trimethoprim-resistant Bacillus anthracis.
Antimicrob Agents Chemother. 2007 Dec;51(12):4447-52. doi: 10.1128/AAC.00628-07. Epub 2007 Sep 17.
4
Crystal structure of the anthrax drug target, Bacillus anthracis dihydrofolate reductase.
J Med Chem. 2007 Sep 6;50(18):4374-81. doi: 10.1021/jm070319v. Epub 2007 Aug 14.
5
MolProbity: all-atom contacts and structure validation for proteins and nucleic acids.
Nucleic Acids Res. 2007 Jul;35(Web Server issue):W375-83. doi: 10.1093/nar/gkm216. Epub 2007 Apr 22.
6
Bivalent ligands derived from Huperzine A as acetylcholinesterase inhibitors.
Curr Top Med Chem. 2007;7(4):375-87. doi: 10.2174/156802607779941215.
8
Parameter estimation for scoring protein-ligand interactions using negative training data.
J Med Chem. 2006 Oct 5;49(20):5856-68. doi: 10.1021/jm050040j.
9
Mycobacterium tuberculosis dihydrofolate reductase is a target for isoniazid.
Nat Struct Mol Biol. 2006 May;13(5):408-13. doi: 10.1038/nsmb1089. Epub 2006 Apr 30.
10
Dihydrofolate reductase inhibitors as antibacterial agents.
Biochem Pharmacol. 2006 Mar 30;71(7):941-8. doi: 10.1016/j.bcp.2005.10.052. Epub 2005 Dec 13.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验